Jefferies Assumes Immunomedics (IMMU) at Buy
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Jefferies assumes coverage on Immunomedics (NASDAQ: IMMU) with a Buy rating and a price target of $5.50 (from $5.00).
Analyst Matthew Andrews commented, "Assuming coverage with a Buy Rating and $5.50 price target. IMMU-132 has generated promising results in Triple Negative breast cancer and we believe clin/reg/CMC progress in 2016 sets the stage for a deal in the coming months ahead of Ph. III start by late 2016/early 2017. Based on '132's TNBC profile and FDA precedent, we assign a 55% probability of Accelerated Approval (AA) based on Ph. II data in 2018."
Shares of Immunomedics closed at $2.50 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on Essendant (ESND) to $18 Following EPS Miss
- Drexel Hamilton Raises Price Target on VMware (VMW) Following 3Q
- Jefferies Raises Price Target on Medidata Solutions (MDSO) to $41; Reiterates Underperform
Create E-mail Alert Related CategoriesAnalyst Comments, Hot New Coverage, New Coverage
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!